The A-TANGO project made significant strides in 2024, reinforcing its commitment to testing safety and efficacy of novel combinatorial therapies for alcohol-related liver disease and ACLF.

A key contribution from EF CLIF was the development of the electronic case report form (eCRF), a digital tool designed to securely collect, manage, and store patient data while ensuring accuracy, consistency, and regulatory compliance. By streamlining data entry and validation, the eCRF will enhance data quality, minimize errors, and enable real-time monitoring, making it a crucial component for the completion of the clinical trial.

The A-TANGO Consortium contributed new insights into ALCLF in the context of alcohol-related liver disease through a study presented at the EASL Congress 2024 in Milan, Italy. Early career scientists from the project, Annarein Kerbert (Leiden University Medical Center, The Netherlands) and Julian Pohl (Charité – Universitätsmedizin Berlin, Germany) shared findings comparing the development of ACLF in the context of either alcohol-associated hepatitis or infections—the two most common precipitants of ACLF in patients with underlying cirrhosis—at the EASL Congress 2024, Milan, Italy. The study revealed distinct organ failure patterns between the two conditions while highlighting similar short-term mortality rates. These findings underline the need for further research into the mechanisms driving disease progression in the context of alcohol-related liver diseases.

Additionally, the European Commission approved an amendment to the A-TANGO Grant Agreement, resulting in a restructuring of the consortium. This included the removal of partner Alpha Bioresearch SL as a beneficiary due to the termination of its participation in the project. Klinera was incorporated into the project by the end of the year to support day-to-day clinical operations.

As A-TANGO moves forward, these achievements set the stage for critical advancements in the understanding and treatment of alcohol-related liver disease. With patient recruitment  about to start and new research directions emerging, the project remains at the forefront of research and innovation in chronic liver disease.